A purified complex of metabolically labeled [ 3 H]lipooligosaccharide (LOS) and recombinant human myeloid differentiation factor 2 (MD-2), [ 3 H]LOSÁMD-2, has been used to demonstrate pM affinity binding interactions with soluble TLR4 ectodomain (TLR4ecd). For measurement of the binding parameters of membrane-bound TLR4, we took advantage of the stability of endotoxinÁMD-2 and tyrosine(s) present on the surface of MD-2 to radioiodinate LOSÁMD-2. Radioiodinated LOSÁMD-2 generated a reagent with an estimated 1:1 molar ratio of [ 125 I] to sMD-2 with 20-fold higher specific radioactivity and TLR4-activating properties comparable to metabolically-labeled LOSÁMD-2. LOSÁMD-2[ 125 I] and [ 3 H]LOSÁMD-2 have similar affinities for soluble FLAG TLR4ecd and for membrane-bound TLR4 in HEK293T/ TLR4 cells. In a similar dose-dependent manner, sMD-2 and LOSÁMD-2 inhibit LOSÁMD-2[ 125 I] binding to TLR4 indicating the pM affinity binding of LOSÁMD-2[ 125 I] is agonist-independent. LOSÁMD-2[ 125 I] allowed measurement of low levels of cell-surface human or murine TLR4 expressed by stable cell lines (2000-3000 sites/cell) and quantitatively measures low levels of 'MD-2-free' TLR4 (est. 250 molecules/cell) in cells co-expressing TLR4 and MD-2. Occupation of 50-100 TLR4/ cell by LOSÁMD-2 is sufficient to trigger measurable TLR4-dependent cell activation. LOSÁMD-2[ 125 I] provides a powerful reagent to measure quantitatively functional human and murine cell-surface TLR4, including in cells where surface TLR4 is potentially functionally significant but not detectable by other methods.
Introduction
TLRs are essential innate immune sensors that couple molecular recognition of specifically conserved and structurally unique microbial molecules to rapid mobilization of innate immune effector systems and induction of adaptive immunity. 1, 2 Substantial progress has been made in deciphering the mechanism(s) of activation and subsequent signal transduction upon TLR engagement by an agonist. However, data are limited with regard to ligand recognition properties of TLRs, including the structural requirements of ligand recognition and the binding parameters of specific ligand:TLR interactions. As a consequence, measurement of receptor activation by various compounds, rather than direct binding, has often been utilized to infer TLR receptor recognition.
TLR4 confers exquisite sensitivity to many different species of invading Gram-negative bacteria (GNB) by virtue of its role in recognition and response to endotoxins (E), unique and abundant surface glycolipids of GNB. Endotoxins are the most potent natural regulators of TLR4 stimulating host inflammatory responses at fmol/ml concentrations of endotoxin, corresponding to as few as 100 invading GNB/ml. The ability of TLR4 to respond to pM concentrations of E does not reflect direct E-TLR4 interactions, but depends on the ordered action of three extracellular and cell surface host proteins: LPS-binding protein (LBP), soluble (s) and glycophosphatidylinositol (GPI)-linked membrane (m)associated forms of CD14 and secreted or TLR4-associated MD-2. [3] [4] [5] [6] [7] [8] LBP, CD14 and MD-2 dramatically alter the physical presentation of E, resulting in amplification of host responsiveness to E. One GNB containing about 10 6 E molecules can be converted to 10 6 TLR4-activating monomeric EÁprotein complexes. 7, 9, 10 Individual E monomers, extracted from GNB or purified E aggregates, form monomeric EÁprotein complexes that, at pM concentrations, engage TLR4 either indirectly (EÁCD14 with MD-2ÁTLR4) or directly (EÁMD-2 with TLR4), and cause receptor and cell activation. TLR4 activation by E requires simultaneous binding of E and TLR4 by MD-2. EÁMD-2 is unique in its ability to directly engage and activate host cells expressing TLR4 without MD-2. 4, 7, 9 The identification and characterization of monomeric EÁMD-2 complexes as potent TLR4 agonists or antagonists, depending on E and/or MD-2 structure, have clearly demonstrated that it is the properties of the EÁMD-2 complex, not E alone, that specifies TLR4 activation or receptor occupancy without activation. 4, [9] [10] [11] In stark contrast to the instability of sMD-2 monomers, [12] [13] [14] [15] [16] the stability and solubility of monomeric EÁMD-2 have permitted the purification of stable, monomeric and active EÁMD-2 complexes. [9] [10] [11] The use of purified and radiolabeled [ 3 H] lipooligosaccharide (LOS)ÁMD-2 in combination with the predicted TLR4 ectodomain (TLR4ecd) has allowed detection and quantitative analysis of specific, high-affinity (pM) EÁMD-2 and TLR4ecd interactions. 7, 17 In addition, the stability of EÁMD-2 and TLR4ecdÁEÁMD-2 complexes has allowed the use of NMR to examine and compare structural properties of [ 13 C]-labeled fatty acyl chains of E in both an agonistic wild type (wt) and an antagonistic mutant MD-2 complex alone and bound to TLR4ecd. 18 While solution studies using TLR4ecd have been informative regarding EÁMD-2 interactions, the ability to extend binding studies to full-length TLR4 present on various cell types has remained elusive owing apparently to the low levels of cell-surface TLR4 on many E-responsive cells and the limits of detection of available reagents, including [ 3 H]EÁMD-2. The stability of EÁMD-2 complexes 9 and the presence of tyrosines on the surface of MD-2 19, 20 suggest that iodination of purified LOSÁMD-2 could provide a reagent of enhanced specific radioactivity with sufficient sensitivity for binding studies to TLR4-containing cells. Both biochemical and X-ray crystal structural data suggest tyrosine residues that are exposed and not involved in sites of interactions with E or TLR4 necessary for EÁMD-2 function. [19] [20] [21] Data presented here indicate that iodination of purified LOSÁMD-2 under gentle conditions generates LOSÁMD-2[ 125 I], a sensitive, high-affinity ligand for TLR4 that has the same functional characteristics as LOSÁMD-2, but with a specific activity ($500,000 cpm/pmol) approximately 20-fold greater than metabolically-labeled [ 3 H]LOSÁMD-2. LOSÁMD-2[ 125 I] provides a high-affinity TLR4 ligand capable of quantifying as few as 100 'free' cell surface TLR4/cell in both human and murine cells, including in cells expressing both TLR4 and MD-2 where levels of free TLR4 have been too low for detection. The sensitivity of the binding assays described here reveal how few TLR4/cell need to be engaged for measurable cell activation, underscoring the remarkable potency of this innate immune sensor. 22, 23 Human serum albumin (HSA) was an endotoxin-free, 25% stock solution from Baxter Health Care (Glendale, CA, USA). Chromatography matrices (Sephadex G10, Sephacryl HR S100 and 200 and Ni 2+ FF-Sepharose) were purchased from GE Healthcare (Piscataway, NJ, USA). BSA, anti-FLAG M2 agarose, and other chemical reagents were from Sigma (St. Louis, MO, USA). Iodogen was purchased from Pierce (Rockford, IL, USA) and used according to the manufacturer's instructions. The stable HEK293 cell line expressing human TLR4 was a generous gift from Dr Jesse Chow (Eisai Research Institute, Andover, MA, USA) and the stable HEK293 cell line expressing murine TLR4 was purchased from Invivogen (San Diego, CA, USA). Conditioned medium containing secreted FLAG-tagged TLR4 ectodomain-vlr-Fc protein used in capture assays was obtained from Freestyle HEK293F cells stably transfected with TLR4 (amino acids 27-527) in a CMV vector containing additional hagfish amino acid sequence at the C-terminal end followed by the Fc domain. The stable transfected cells were a generous gift from Dr Richard Tapping (University of Illinois, Urbana, IL, USA). Control conditioned medium (i.e. not containing FLAG TLR4ecd) obtained from HEK293 cells was used as a negative control. The pCMV-FLAG-TLR4 vectors encoding either TLR4 wt or mutant D299G.T399I were a generous gift from Dr Stefanie Vogel (University of Maryland, Baltimore, MD, USA). The IL-8 ELISA kit (BD OptEIA) was purchased from BD Biosciences (San Diego, CA, USA) and used according to manufacturer's instructions. Binding data were analyzed using GraphPad Prism 5 Software (La Jolla, CA, USA).
Materials and methods Materials

Preparation of recombinant human MD-2
Recombinant human His 6 -MD-2 was generated as described previously, 9 except that cDNA encoding human MD-2 was optimized for transcription in High Five cells (Tricoplusia ni) by DNA 2.0 (Menlo Park, CA, USA) generating a designer gene for human MD-2. The cDNA encoding human MD-2 was inserted using SacII and XhoI restriction sites into the baculovirus transfection vector, pBAC3 (Novagen, Billerica, MA, USA) that contains a six-residue polyhistidine (His 6 ) tag at the N-terminal end and a 5 0 flanking signal sequence (gp64) to promote secretion of the expressed protein from the insect cells. Baculovirus stocks containing the gene for His 6 -MD-2 were generated by transfection of BacVec3000 and plasmid into Sf9 cells using the BacVec3000 kit from Novagen, according to the manufacturer's instruction. The generated baculovirus was then amplified in Sf9 cells and used to infect High Five TM (Invitrogen, Grand Island, NY, USA) insect cells in serum-free medium for protein production. Large-scale (20 l) preparations of conditioned insect medium containing secreted His 6 -MD-2 were produced by BlueSky Biotech (Worcester, MA, USA).
Preparation of LOSÁMD-2 complexes
We have recently described the preparation of endo-toxinÁalbumin complexes (M r $70,000) and conditions in which endotoxinÁalbumin complexes react with conditioned insect medium containing sMD-2 to generate endotoxinÁMD-2. 18 In a typical purification, isolated LOSÁalbumin complexes (1 mg LOS, 200 nmol) were incubated with conditioned insect medium containing secreted human His 6 -sMD-2 (2 l, 90 nmol, $1 ug/ml sMD-2) for 3 h at 37 C with gentle shaking. The reaction mixture was dialyzed (Spectrapor 1, MMCO 3500) against 20 mM phosphate, 0.5 M NaCl, 5 mM imidazole, pH 7.6, 'binding buffer'.
The dialyzed material was loaded onto Ni FF Sepharose (5 cm Â 25 cm) using GEHealthcare Explorer fast protein liquid chromatography at 4 C at a flow-rate of 3 ml/min. After washing the column with 20 mM imidazole in binding buffer, the adsorbed material was eluted by an imidazole gradient in 'binding buffer' (pH 7.6). The peak of [ 14/13 C]LOSÁMD-2 eluted toward the end of the 0.5 M imidazole gradient. The radioactive fractions were combined and concentrated using a Centriplus-70 (Millipore, Billerica, MA, USA) to a final volume $2 ml and then injected onto a Sephacryl S100 column (1.6 Â 100 cm) equilibrated in 20 mM phosphate, 150 mM NaCl, pH 7.1. The peak fractions containing radioactivity were combined and concentrated using a Millipore Centricon MMCO 10 K to a final volume 0.5-1 ml. Coomassie blue stain of SDS-PAGE PhastGel, 10-15% gradient gel (GEHealthcare), confirmed the purity of the sample. 18 LOSÁMD-2 F126A complexes were prepared and purified using an identical procedure. 18 Complexes of [ 3 H]LOSÁMD-2 (25,000 cpm/pmol) used in analytical binding and cell activation were generated as described previously. 7, 9, 22 Radioiodination of LOSÁMD-2
Iodination was done at room temperature in borosilicate tubes coated with 10 ug IODOGEN that had been delivered in chloroform followed by removal of the solvent under a stream of nitrogen. To an iodogen-containing tube, 70 ml 20 mM phosphate, 150 mM NaCl, pH 7.1 (buffer A) was added, followed by 9.2 mg MD-2 in the form of LOSÁMD-2 (20 ml containing 100 ng LOS and 460 ng MD-2 per ml). Iodine stock solution {0.5 mCi of Na 125 I (1000 Ci/mmol [ 125 I], Perkin Elmer, Waltham, MA, USA} (10 ml in buffer A) was added to the tube and the sample was mixed occasionally for 7-9 min. Sodium metabisulfite (10 mg/ml buffer A, 10 ml) was added to stop the reaction and the sample was applied to a Sephadex G10 column (1 cm Â 16 cm) equilibrated in buffer A, 0.1% BSA. Fractions (1 ml) were collected and an aliquot counted to determine the peak of radioactivity that eluted near the void volume containing LOSÁMD-2. Application of [ 3 H]LOSÁMD-2 to G10 Sephadex under the same conditions was used to establish the elution pattern and recovery (100%) of [ 3 H]LOSÁMD-2. Radioactivity determinations for radioiodinated samples were done in the Packard Cobra (Meridan, CT, USA) II autogamma counter. The void volume radioactive peak fraction had the greatest % of trichloroacetic acid (TCA) precipitable counts (80-85%) and was further purified from free [ 125 I] by dilution in buffer A, followed by concentration using Millipore Ultracel MMCO 10 K to the original volume. This process of dilution and concentration was repeated three times. The recovered retentate was diluted with buffer A to a final volume of 1 ml. This recovered iodinated product was re-evaluated by TCA precipitation; 98% of the [ 125 I] counts were TCA-precipitable, i.e. protein-bound. Iodinated LOSÁMD-2 was aliquoted and stored at -80 C; material was used within 2-3 months of production. Specific radioactivity of the final product was approximately 500,000 cpm/pmol LOSÁMD-2[ 125 I]. Iodination of LOSÁMD-2 was repeated three times with virtually identical results in recovery, specific radioactivity and functional properties.
To verify that the purified iodinated product corresponded to LOSÁMD-2[ 125 I], an aliquot of this sample (0.04 pmol, 18,000 cpm), as well as [ 3 H]LOSÁMD-2 (0.2 pmol, 5,500 cpm), were applied to Sephacryl S200 (1.6 cm Â 60 cm) and eluted in PBS, 0.1% HSA, pH 7.4, on the AKTA Purifier10 at a flow rate 0.5 ml/min. The Sephacryl S200 column was calibrated by application of HSA and BioRad gel filtration standards (BioRad, Hercules, CA, USA) containing thyroglobulin, IgG, ovalbumin, myoglobin and vitamin B12. Fractions (1 ml) were evaluated for radioactivity-LOSÁMD-2[ 125 I] using Packard Cobra II autogamma counter and Anti-FLAG agarose co-capture of the product of LOSÁMD-2 reaction with FLAG TLR4ecd-vlr Co-capture assay of radiolabeled LOSÁMD-2 binding to FLAG-tagged TLR4 ectodomain was performed as described previously. 7, 17 Increasing concentrations of [ 3 H]LOSÁMD-2 (25,000 cpm/pmol) or LOSÁMD-2[ 125 I] (500,000 cpm/pmol) were incubated with control conditioned medium or conditioned medium containing FLAG TLR4ecd-vlr (10 ml) for 30 min at 37 C (total volume 0.4 ml in PBS, 0.1% HSA, pH 7.4). After incubation, the samples were mixed 1 h at 25 C (room temperature) on a rotating wheel with anti-FLAG-agarose (30 ml 1:1 slurry) equilibrated in the same buffer. The samples were spun at 2000 g for 5 min at 4 C, supernatant was removed and the beads were then washed twice with 1 ml cold PBS, 0.1% HSA, pH 7.4. The supernatants, washes and radioactivity associated with the affinity gel ('capture') were evaluated by liquid scintillation spectroscopy using a Beckman LS6500 scintillation counter for tritiated samples and by direct counting in a Packard Cobra II autogamma counter for iodinated samples. In analysis of the data, incubations containing control conditioned medium was used to determine non-specific binding (capture) in the dose curve for both ligands.
TLR4-dependent binding of LOSÁMD-2 to cells
For experiments with transfected cells, T75 flasks of HEK293T cells were grown to confluence in DMEM, 10% FCS and transfected with 10 mg control empty vector or pCMV-FLAG containing either wt TLR4 or TLR4 D299G. T399I using either PolyFect (Qiagen, Valencia, CA, USA) or Lipofectamine2000 (Invitrogen) in OptiMEM I (Gibco, Grand Island, NY, USA) medium followed by the addition of DMEM, 0.1% HSA. After 12 h, the medium was changed to DMEM, 10% FCS; after an additional 24 h, the cells were harvested, spun and re-suspended (1 ml) in PBS, 0.1% HSA, pH 7.4. For each preparation, the number of viable cells was determined in the re-suspended pellet by trypan blue staining and cell counting with a hemacytometer. Cell count was also determined using the Accuri flow cytometer. The cells were distributed in 1.5 ml siliconized microfuge tubes (approximately 1 or 2 Â 10 6 cells/tube as indicated in figure legends) and brought to 1 ml with PBS, 0.1% HSA.
For experiments with stable HEK293 cell lines, control parent cells (not expressing TLR4), and transformants expressing either human or murine TLR4, cells were grown to confluence in T75 flasks, dislodged, spun and re-suspended in PBS, 0.1% HSA, pH 7.4, for distribution (approximately 2 Â 10 6 cells/tube) into 1.5 ml siliconized microtubes and brought to a final volume of 1 ml in the same buffer.
To determine binding parameters on membranebound TLR4, increasing concentrations of [ 3 H]LOSÁMD-2 or LOSÁMD-2[ 125 I] were added to control and TLR4-containing cells in duplicate, and the samples were incubated for 30 min at 37 C on an orbital rocker. Parent or mock transfected cells provided a control of non-specific cell binding for each ligand at each dose. After 30 min, the samples were placed on ice and spun at 2000 g for 5 min at 4 C. The supernatants were removed and the cell pellets were washed twice with ice cold PBS, 0.5% HSA, pH 7.4 (1 ml). For cells bound with LOSÁMD-2[ 125 I], radioactivity associated with the cells, in the supernatants and washes was determined by direct counting in the gamma counter (Packard Cobra II autogamma counter). For cells bound with [ 3 H]LOSÁMD-2, the pellet was re-suspended and radioactivity in the re-suspended pellet, supernatant and washes was determined by liquid scintillation spectroscopy (Beckman LS 6500 scintillation counter). Binding of [ 3 H]LOSÁMD-2 or LOSÁMD-2[ 125 I] to control cells was subtracted from the total [ 3 H]LOSÁMD-2 or LOSÁMD-2[ 125 I] bound to the TLR4 expressing cells at each dose of LOSÁMD-2 to calculate specific TLR4dependent binding. Based on 1:1 mol/mol binding of LOSÁMD-2 to TLR4 7,18,21 and the known specific radioactivity of LOSÁMD-2[ 125 I], the number of molecules of TLR4 on the cell surface/cell could be derived from the B max value acquired by Scatchard analysis of binding data on 2 Â 10 6 cells/sample.
For experiments examining inhibition of LOSÁMD-2[ 125 I] binding to TLR4 in transiently transfected cells, increasing doses of sMD-2 or LOSÁMD-2 were added to the cells (2 Â 10 6 /sample) before addition of LOSÁMD-2[ 125 I] (60 pM). Binding experiments were then performed as described earlier for 30 min at 37 C. A similar binding assay was performed with LOSÁMD-2[ 125 I] using bone marrow derived macrophages (BMDM) from wt and TLR4 -/-C57BL/6 mice that were immortalized by transformation with a J2 transforming retrovirus expressing myc and raf. 25 These immortalized BMDM (iBMDM) were developed and generously provided by Dr Katherine Fitzgerald (University of Massachussetts Medical School, Worcester, MA, USA). The cells were maintained in DMEM, high Glc, 10% heat inactivated FBS supplemented with ciprofloxin (10 mg/ml), dislodged for binding assays with Versene (Gibco), and cell binding was performed in solution as described earlier. At each dose of LOSÁMD-2[ 125 I], samples were incubated AE sMD-2 (5 nM), a dose that saturated TLR4, to determine sMD-2-sensitive cell binding of LOSÁMD-2[ 125 I].
For all cell-binding experiments, the number of cells/ sample was normalized by cell counting and gating using the Accuri flow cytometry apparatus. Total protein/aliquot of each cell preparation was measured using the BCA protein assay (Pierce) to confirm similar cell mass/sample.
Cell activation by LOSÁMD-2
Cell activation by [ 3 H]LOSÁMD-2, [ 13/14 C]LOSÁMD-2 or LOSÁMD-2[ 125 I] in control (no TLR4) and TLR4expressing cells was determined on a portion of the cells described above that had been dislodged, re-suspended, and counted before use in binding experiments. This permitted a direct correlation between TLR4-dependent cell binding and cell activation by LOSÁMD-2 in the same cell population. Cells were transferred to 96well plates-approximately 10 5 cells/well in 0.2 ml. Cells were stimulated with increasing concentrations of [ 3 H]LOSÁMD-2 or LOSÁMD-2[ 125 I] for 6 h before the supernatants were collected and secreted IL-8 was measured in the medium using the BD OptEIA human IL-8 ELISA assay (BD Biosciences). In the case of iBMDM cells (wt, TLR4 -/-, and CD14 -/-), cells were washed twice with warm (37 C) PBS, pH 7.4, and incubated with the indicated concentrations of LOSÁMD-2 wt or LOSÁMD-2 F126A for 18 h at 37 C in DMEM/ 0.1% HSA. Cell activation was assessed by measuring accumulation of extracellular TNF-a by ELISA (BD Biosciences).
Results
Radioiodination of LOSÁMD-2
We have previously described the generation of complexes of LOSÁMD-2 on a preparative scale using recombinant human sMD-2 generated by baculoviral infection of insect cells and metabolically labeled ([ 14/13 C]) endotoxin, LOS, from N. meningitidis. 18 Purified complexes of LOSÁMD-2 were isolated by a combination of metal chelation and size exclusion chromatographies.
While metabolically-labeled [ 3 H]LOSÁMD-2 has proven useful in quantifying the high-affinity binding of endotoxinÁMD-2 with the TLR4 ectodomain in solution, 7, 17 the apparently low levels of membrane-bound TLR4 receptors/cell in many endotoxin-responsive cells necessitated development of a ligand that could be detected and measured more sensitively when levels of TLR4/cell and/or the number of TLR4-expressing cells available for study were limited. To generate such a reagent, we have taken advantage of the stability of LOSÁMD-2 and the presence of several tyrosines ( Figure 1A ) on the surface of human MD-2, including several residues (shown in blue in Figure 1A ) that are not required for interactions with endotoxin and/or TLR4. 11, [26] [27] [28] [29] Tyrosines that have been shown to be essential for activity based on mutagenesis studies for both murine and human sMD-2 are shown in red (Y34, 36, 76, 102, and 131) in Figure 1A . 11, [26] [27] [28] [29] A purified complex of human LOSÁMD-2 was iodinated under mild reaction conditions using the reagent Iodogen. A monomeric LOSÁMD-2 complex in which 98% of the [ 125 I] counts are protein-bound, as judged by precipitation by icecold 10% TCA eluted co-incident with [ 3 H]LOSÁMD-2 on Sephacryl S200 exclusion chromatography ( Figure  1B) , confirming that LOSÁMD-2[ 125 I] remains a monomeric complex. LOSÁMD-2 is dissociated by SDS treatment. The peak of [ 125 I] recovered from application of LOSÁMD-2[ 125 I] to, and elution from, Sephacryl S200 co-migrated on SDS-PAGE with MD-2 (data not shown), consistent with radioiodination of MD-2 in the LOSÁMD-2 complex. LOSÁMD-2[ 125 I] recovered after removal of free iodine had a specific radioactivity $500,000 cpm/pmol. Based on the specific radioactivity of the [ 125 I], the amount of MD-2 used in the reaction, and the amount of [ 125 I]product recovered in the peak fraction, the calculated molar ratio of [ 125 I] to MD-2 in LOSÁMD-2[ 125 I] is approx. 1:1.
Comparison of the TLR4-binding properties of metabolically-labeled [ Figure 2A and B, Scatchard analyses of these data show specific, saturable and high-affinity binding of LOSÁMD-2[ 125 I] to TLR4ecd that is similar to binding of [ 3 H]LOSÁMD-2 to FLAG TLR4ecd:
To extend the studies to interactions with full-length TLR4 so that binding of LOSÁMD-2 and subsequent TLR4-dependent cell activation could be compared, Figure 3A, B) . Non-specific binding to control transfected cells accounted for <10% of the total binding (see Figure 3A and B inserts) at LOSÁMD-2 concentrations K d . Specific TLR4 binding was similar at 4 C, indicating that binding was to TLR4 at the cell surface (data not shown). The derived B max for TLR4-dependent LOSÁMD-2 binding to the transiently transfected cells indicates an average of approximately 10,000 TLR4s/cell on the cell surface. Comparison of dose-dependent TLR4 binding ( Figure 3A, B) and TLR4-dependent cell activation ( Figure 3C High-affinity binding of LOSÁMD-2 to cellular TLR4 corresponds to agonist-independent binding of MD-2 to TLR4 Two functionally and topologically distinct binding sites within the TLR4 ectodomain for ligandÁMD-2 have been defined: (i) sites within N-and central-leucine-rich repeat (LRR) regions of the TLR4ecd mediating agonist-independent interactions of MD-2 and of endotoxinÁMD-2 with TLR4 within a binary (MD-2ÁTLR4) and ternary (endotoxinÁMD-2ÁTLR4) complex, respectively, and (ii) sites within the C-terminal LRR region of TLR4 in one ternary complex mediating interactions with TLR4-activating endotoxinÁMD-2 of a second neighboring ternary complex. 19, 21 As shown in Figure 4 , sMD-2 alone was as potent as TLR4-activating LOSÁMD-2 in causing dosedependent inhibition of LOSÁMD-2[ 125 1] binding to cell surface TLR4. These findings indicate that agonistindependent interactions of LOSÁMD-2 with cell surface TLR4, i.e. interactions within a single ternary complex, are sufficient to confer the high-affinity pM interactions observed.
Use of LOSÁMD-2[ 125 I] to measure low levels of functional cell surface TLR4
An important advantage of LOSÁMD-2[ 125 I] versus [ 3 H]LOSÁMD-2 should be its ability to measure levels of functional surface TLR4 in endotoxin-responsive cells that express very low levels of surface TLR4. To test this feature more directly we compared TLR4-dependent cell binding of [ 3 H]LOSÁMD-2 and of LOSÁMD-2[ 125 I] to stable transformants of HEK293 cells (HEK/TLR4 cells) that we anticipated expressed lower levels of TLR4/cell than the transiently-transfected cells. Scatchard analysis of dosedependent binding of LOSÁMD-2[ 125 I] to these cells, as well as parental HEK293 cells as a negative control, confirmed this prediction. TLR4-dependent high-affinity binding of LOSÁMD-2[ 125 I] to the stable HEK/ TLR4 cells (K d ¼ 734 AE 40 pM) was similar to the transiently transfected cells with, on average, 4-5-fold fewer LOSÁMD-2-reactive TLR4 receptors/cell, i.e. B max ¼ 12.7 AE 0.3 pM/2 million HEK/TLR4 cells ml -1 corresponding to approximately 2500 surface TLR4/ cell ( Figure 5B, C) . In contrast, the lower signal/ noise (i.e. TLR4-dependent/non-specific LOSÁMD-2 binding) in the stably transformed HEK/TLR4 cells precluded reliable Scatchard analysis with the metabolically labeled [ 3 H]LOSÁMD-2 ( Figure 5A ). In these cells, TLR4-dependent cell activation was readily detected when cells were incubated with 6-20 pM LOSÁMD-2 ( Figure 5D ), corresponding to approximately 50-100 surface TLR4 occupied by TLR4activating LOSÁMD-2. 
Comparison of LOSÁMD-2 binding to wt and polymorphic variant TLR4
Two missense TLR4 variants, D299G and T399I, have been described that can result in reduced responsiveness to endotoxin. [30] [31] [32] [33] [34] [35] We have reported previously that wt surface wt and D299G.T399I TLR4 were compared, but the lower levels of functional surface variant TLR4 precluded quantitative analysis by Scatchard analysis. 17 We took advantage of the more sensitive measurement of cell surface TLR4 possible with LOSÁMD-2[ 125 I] to re-examine the functional levels of cell surface wt and D299G.T399I TLR4 using the same transient transfection conditions in HEK293T cells used previously. 17 Under these conditions, there was similar transfection efficiency and transcription of expression vectors encoding wt and D299G.T399I TLR4, as confirmed by qRT-PCR. 17 Scatchard analysis of LOSÁMD-2[ 125 I] binding, as described earlier, confirmed similar high affinity of LOSÁMD-2 for wt and D299G.T399I TLR4 (K d ¼ 528 AE 100 for wt TLR4 and 531 AE 74 pM for D299G.T399I TLR4) and reduced steady-state surface expression of the variant TLR4 (with 2 Â 10 6 cells/ml B max ¼ 12.7 AE 0.9 pM vs. 4.0 AE 0.2 pM for cells expressing wt vs. D299G.T399I TLR4; Figure 6A, B) . Reduced surface expression of D2996.T399I TLR4 was paralleled by reduced cell activation by LOSÁMD-2, especially at very low concentrations of added LOSÁMD-2 ( Figure 6C ). When dose-dependent LOSÁMD-2-induced cell activation was expressed as a function of the amount of TLR4dependent LOSÁMD-2 binding ( Figure 6D ), there was no diminution in the ability of LOSÁMD-2-occupied D299G.T399I versus wt TLR4 to trigger cell activation.
High-affinity binding of LOSÁhuman MD-2 to human and murine TLR4
Our studies have used endotoxinÁMD-2 complexes containing human MD-2 exclusively, in part because of the much greater difficulty to recover functional secreted murine MD-2. 36 Both agonist-independent and agonist-dependent interactions of murine MD-2 with TLR4 exhibit pronounced species selectivity, whereas these interactions are similar between endotoxinÁhuman MD-2 and murine, as well as human, TLR4. 27, [36] [37] [38] [39] [40] [41] Therefore, we expected that LOSÁMD-2[ 125 I] would display similar high-affinity binding to cells expressing murine TLR4. A stable transformant line of HEK293 cells expressing murine TLR4 was examined to test this prediction. Comparison by Scatchard analysis of TLR4-dependent cell binding of LOSÁMD-2[ 125 I] to cells expressing human TLR4 ( Figures 3B, 5A and 6A) versus cells expressing murine TLR4 (Figure 7 ) demonstrated similar high-affinity binding of LOSÁMD-2[ 125 I] to human (K d range from 528-730 pM) and murine (K d ¼ 572 AE 15 pM) TLR4.
Detection of LOSÁMD-2-reactive TLR4 in cells expressing both TLR4 and MD-2
The ability of sMD-2 to fully inhibit LOSÁMD-2[ 125 I] binding to TLR4 (Figure 4 ) strongly suggests that LOSÁMD-2[ 125 I] binding to cell surface TLR4, as previously shown for TLR4ecd, 7 is specific for TLR4 molecules that are not already occupied by MD-2. This property implies that LOSÁMD-2[ 125 I] binding could be used to measure levels of 'MD-2-free' TLR4 in cells expressing both TLR4 and MD-2. Crucial to this assay is that inhibition of cell binding of LOSÁMD-2[ 125 I] by sMD-2 is TLR4-dependent, i.e. sMD-2 does not inhibit non-specific cell binding of LOSÁMD-2[ 125 I]. We therefore compared cell binding of LOSÁMD-2[ 125 I] to murine BMDM cell lines (iBMDM) derived from wt and TLR4 -/mice. The wt cell line provided a test case for probing for the presence of minute numbers of membrane-bound TLR4 'free' of pre-bound MD-2, as indicated by LOSÁMD-2[ 125 I] cell binding that is inhibited by sMD-2. The TLR4 -/cells were used to test that sMD-2-sensitive LOSÁMD-2[ 125 I] cell binding was TLR4-dependent. There were low levels of non-specific (TLR4-independent) binding of LOSÁMD-2[ 125 I] to the TLR4-null cells (<0.5% of total LOSÁMD-2[ 125 I] added) that was unaffected by added excess sMD-2. Saturable sMD-2-sensitive binding of LOSÁMD-2[ 125 I] was seen only in the wt murine iBMDM ( Figure 8A) where similar sMD-2-insensitive, non-specific (TLR4independent) binding of LOSÁMD-2[ 125 I] as in TLR4null cells was also seen. Scatchard analysis of the sMD-2-sensitive binding of LOSÁMD-2[ 125 I] to the wt cells revealed a K d ¼ 448 AE 194 pM ( Figure 8A ). The high affinity and TLR4-dependence of the sMD-2-sensitive binding of LOSÁMD-2[ 125 I] measured are consistent with the presence of a subpopulation of macrophage cell surface TLR4 that is reactive with LOSÁMD-2[ 125 I], i.e. corresponds to 'MD-2-free' TLR4. Scatchard analysis indicated 0.9 AE 0.1 pM sites per 2 million iBMDM ml -1 (B max ), i.e. approximately 250 'MD-2-free' TLR4/cell. To confirm the presence of functional 'MD-2-free' TLR4 in wt mouse iBMDM, we compared activation as measured by extracellular accumulation of TNF-a of these cells by LOSÁMD-2 wt versus by LOSÁMD-2 F126A. In wt iBMDM, LOSÁMD-2 wt can activate TLR4 both by direct engagement of 'MD-2-free' TLR4 7,9 and by transfer of bound endotoxin (LOS) from MD-2 to cellular mCD14 followed by transfer of LOS to and activation of cellular MD-2ÁTLR4 heterodimer. 42 LOSÁMD-2 F126A can also transfer LOS to mCD14, 11, 42 but binding of this mutant complex to TLR4 directly induces little or no activation of TLR4. 11, 18 Thus, the presence of 'MD-2-free' TLR4 in wt mouse iBMDM should result in more cell activation by LOSÁMD-2 wt than by LOSÁMD-2 F126A. The data in Figure 8B support this prediction by showing more cell activation by LOSÁMD-2 wt at each dose of wt and mutant LOSÁMD-2 tested. This difference is consistent with the added contribution of activation of 'MD-2-free' TLR4 by LOSÁMD-2 wt to the activation achieved by both wt and mutant complexes via transfer of LOS to cellular MD-2ÁTLR4 through mCD14. Similar cell activation assays using iBMDM derived from CD14 -/mice showed cell activation by LOSÁMD-2 wt, but little or no activation by LOSÁMD-2 F126A (Figure 8C ), confirming the ability of LOSÁMD-2 wt to induce CD14-independent activation of TLR4 by direct engagement and activation of 'MD-2-free' TLR4 in these cells. Note that the greater difference in cell activation by LOSÁMD-2 wt versus LOSÁMD-2 F126A in wt murine iBMDM was most apparent at the lower doses of LOSÁMD-2 tested ( 200 pM), consistent with the high-affinity engagement and activation of 'MD-2-free' TLR4 by LOSÁMD-2. 
Discussion
The studies presented herein describe the preparation and characterization of an iodinated endotoxinÁMD-2 complex, LOSÁMD-2[ 125 I], as a highly sensitive and specific TLR4 ligand that provides, for the first time, a reagent that can be used directly to detect and characterize the number of TLR4 receptors on cells that contain TLR4, but lack MD-2. Using 1-2 Â 10 6 cells/ ml in incubations with LOSÁMD-2[ 125 I], we could detect as few as $100 cell surface TLR4/cell and demonstrate that this is a sufficient number of TLR4 receptors to produce measurable TLR4-dependent cell activation when engaged by activating endotoxinÁMD-2 complexes. It was possible to detect and quantify, for the first time, 'free' TLR4 (i.e. TLR4 without pre-associated MD-2) on the surface of cells expressing both TLR4 and MD-2 by utilizing the ability of added sMD-2, in substantial molar excess, to selectively inhibit TLR4-dependent cell binding of LOSÁMD-2[ 125 I] (Figure 8 ). The closely similar binding of LOSÁMD-2[ 125 I] to human and murine TLR4 (Figures 3, 5, 7 and 8) is consistent with earlier evidence, 27, [36] [37] [38] [39] [40] [41] suggesting similar functional interactions of human MD-2 with human and murine TLR4, and extends the applicability of this new reagent to an array of human and murine cells and tissues. Essential to the utility of LOSÁMD-2[ 125 I] is its very high specific radioactivity (approximately 500,000 cpm/pmol) and retention of the TLR4-binding and TLR4-activating properties of metabolically-labeled LOSÁMD-2 (Figures 2 and 3) . These features suggest that iodination under the conditions presented herein do not affect essential tyrosines or features of MD-2 that are necessary for stability of endotoxinÁMD-2, or key to TLR4 recognition and activation. LOSÁMD-2[ 125 I] binds to both TLR4ecd in solution, as well as cell surface, transmembrane TLR4 in transiently transfected cells with the same high affinity as [ 3 H]LOSÁMD-2. An improved method of transient transfection of HEK293T cells with TLR4 resulted in sufficient presentation of TLR4 on the membrane-surface to allow for a saturation curve and Scatchard analysis of bound [ 3 H]LOSÁMD-2 so a direct comparison of its binding features could be made with LOSÁMD-2[ 125 I].
Comparison of the binding affinity of either [ 3 H]LOSÁMD-2 or LOSÁMD-2[ 125 I] to membranebound TLR4 versus TLR4ecd in solution indicates a slightly lower affinity of LOSÁMD-2 for transmembrane TLR4 (K d $200 pM for TLR4ecd versus $500 pM for membrane-bound TLR4). These findings are consistent with the view that all binding interactions between LOSÁMD-2 and TLR4 occur within the ectodomain of TLR4, presumably explaining the efficient binding we observe at 4 C. The basis of the small difference in the K d of interactions of LOSÁMD-2 with TLR4ecd versus full-length transmembrane TLR4 is not known, but could reflect constraints to molecular motion of TLR4 imposed by insertion of full-length TLR4 into the membrane in comparison to more freely 'tumbling' TLR4ecd in solution.
The ability of pM endotoxin concentrations to activate TLR4 is consistent with the role of TLR4 as a sentinel for early detection of even small numbers of invading GNB. However, these data alone do not indicate how many TLR4 receptors on the surface of endotoxin-responsive cells need to be occupied to trigger measurable TLR4-dependent cell activation. The unique ability of LOSÁMD-2 to directly engage and activate TLR4 together with the very high specific radioactivity of LOSÁMD-2[ 125 I] made it possible to quantify the number of cell surface TLR4s needed to be occupied by an activating ligand, LOSÁMD-2, to trigger cell activation. Comparison of dose-dependent TLR4-dependent cell binding and activation by LOSÁMD-2[ 125 I] revealed that, in transiently transfected HEK293 cells, no more than 10-20% maximal occupancy of cell surface TLR4 is needed for maximal cell activation and that occupancy of as little as 1-2% of surface TLR4, corresponding to around 100-200 TLR4/cell, is sufficient for appreciable cell activation, as measured by extracellular accumulation of IL-8 ( Figure 3 ). Data in stable transformants of HEK293 cells expressing TLR4 indicate that, in these cells, occupancy of as few as 50-100 TLR4/cell is sufficient for measurable TLR4 activation ( Figure 5 ). These findings demonstrate dramatically both the sensitive-low K d -and robust-small number of activated receptors sufficient for graded cellular responses-properties of TLR4, fully consistent with its sentinel role in innate immune recognition and response to invading GNB. The small number of engaged TLR4 sufficient for cell activation underscores the importance of sensitive and quantitative detection of TLR4 that LOSÁMD-2[ 125 I] provides. If dimerization of TLR4-activating ternary complexes (e.g. LOSÁMD-2ÁTLR4) is required for TLR4 activation by endotoxin, our data strongly suggest that dimerization occurs remarkably efficiently, even when there are only 50-100 TLR4-activating ternary complexes within an entire cell surface.
An example in which changes in steady-state levels of functional surface TLR4 expression affect cellular response to endotoxin is illustrated by our comparative studies of wt and variant D299G.T399I TLR4 expression in transfected HEK293T cells. 17 The high specific radioactivity of LOSÁMD-2[ 125 I] made possible full saturation curves and Scatchard analysis of LOSÁMD-2 binding to these cells, and confirmed and extended our earlier evidence that the principal effect of the combined D299G and T399I substitutions within the TLR4 ectodomain is on the steady-state levels of functional surface TLR4 and not the intrinsic functional properties of the expressed TLR4 molecule ( Figure 6A, B , D). 17 The reduced responsiveness of transfected cells expressing D299G.T399I rather than wt TLR4 was most apparent at low doses of LOSÁMD-2 ( Figure  6C ), i.e. conditions in which the reduced surface expression of variant TLR4 resulted in levels of LOSÁMD-2occupied variant TLR4 below the threshold needed for maximal TLR4-dependent cell activation. However, as seen in Figure 6D , when data were normalized for the amount of LOSÁMD-2 bound to available wt or D299G.T399I TLR4, a similar degree of cell activation was observed, demonstrating that LOSÁMD-2-occupied variant TLR4 had an undiminished ability to trigger cell activation. The absence of measurable exchange between MD-2 bound to LOS in the monomeric LOSÁMD-2 complex with even 100-fold molar excess sMD-2 or LOSÁMD-2, within the 30 min time frame of our experiments (data not shown), 42 (Figure 4 ) strongly suggests that 'agonist-independent' interactions of MD-2 with the TLR4 ectodomain principally drive the pM binding of LOSÁMD-2[ 125 I] to cell surface TLR4. Recent X-ray crystallographic analyses of MD-2ÁTLR4ecd and ligandÁMD-2ÁTLR4ecd complexes [19] [20] [21] have helped to define the sites within the TLR4 ectodomain, apparently mediating these agonist-independent interactions. Our findings suggest that assays of TLR4-dependent LOSÁMD-2[ 125 I] binding could be used to further define the structural determinants within TLR4, important not only for interactions with TLR4-agonist and TLR4-antagonist ligandÁMD-2, but also with ligand-free MD-2, as needed for biogenesis of MD-2ÁTLR4 heterodimers. Competition assays of LOSÁMD-2[ 125 I] binding to TLR4 with other putative agonists of TLR4, such as aero-allergens, for example Der p 2, that are structurally and functionally related to MD-2, [43] [44] [45] [46] should also help to define the molecular and structural bases of the TLR4-dependent actions of these compounds.
Most cells expressing TLR4 also express MD-2. Given the pM interactions between ligand-free MD-2 and TLR4 that we have described, it has been generally presumed that in these cells surface TLR4 is expressed as a pre-formed heterodimer with MD-2. Thus, actions of exogenously generated ligandÁMD-2-like complexes, such as Der p 2, would be largely restricted to those few cell types (e.g. airway epithelial and human corneal cells 15, 47, 48 ) that express TLR4 with little or no MD-2 under resting conditions. Our ability to measure specifically sMD-2-sensitive LOSÁMD-2[ 125 I] binding to 'free' TLR4 in murine iBMDM suggests a broader range of cell types expressing cell surface functional TLR4 without MD-2. Our findings indicate that a potentially broader range of host cells may be responsive to MD-2-related aero-allergens, as well as extracellular endotoxinÁMD-2 complexes that could be formed under inflammatory conditions when expression and secretion of sMD-2 are up-regulated. 47, [49] [50] [51] [52] Our ability to produce ligandÁMD-2[ 125 I] that are either TLR4 agonists or antagonists, and to specifically measure 'free' TLR4 in both human and murine cells by assay of sMD-2-sensitive ligandÁMD-2[ 125 I] cell binding, should greatly facilitate future efforts to better define the possible sites and roles of 'MD-2-free' TLR4 in the actions of both endogenous ligandÁMD-2 and other putative agonists of TLR4 that may need to engage TLR4 similarly to produce their immune effects.
Increasing evidence suggests even wider physiologic and pathophysiologic roles of TLR4 mediated, at least in part, by interactions of exogenous and/or endogenous host compounds-structurally unrelated to E-with MD-2ÁTLR4 or perhaps TLR4 alone. [53] [54] [55] [56] [57] The compounds include a diverse range of molecules [damage associated molecular pattern molecules (DAMPS)], including viral proteins, parasite glycolipids, host proteins, glycosaminoglycans, hemin and lipids. 17, [53] [54] [55] [56] [57] [58] In contrast to the insights that have been gained concerning the mechanism of E-induced MD-2ÁTLR4 activation, little is known about how these other putative TLR4 agonists affect TLR4 function and if their action is MD-2 dependent. Competition in binding assays with LOSÁMD-2[ 125 I] can be used to test if these DAMPS interact with TLR4 ectodomain in a manner analogous to ligandÁMD-2.
